Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt small index

Ulcerative Colitis (UC): early-phase trial registry

10 of 18 indexed Ulcerative Colitis (UC) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #953 of 28,707 conditions by registered trial count.

18 US clinical trials · 10 currently recruiting · #953 of 28,707 conditions by registered trial count

Ulcerative Colitis (UC): 18 US clinical trials tracked, 10 recruiting.

Ulcerative Colitis (UC) is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 5 of these trials.

Enrollment posture brief

Registry condition ulcerative-colitis-uc

OPEN 10 | RECR 56% | LATE 3 | EARLY 6 | RANK #953 | SPON 5

Nearest open-share peer: Acute Lymphoblastic Leukemia, Pediatric (56% recruiting · 9 trials)

Ulcerative Colitis (this)56%Arrhythmias, Cardiac27.8%Androgenetic Alopecia16.7%Anemia, Sickle Cell16.7%Acquired Immunodeficiency Sy5.6%
Open-enrollment share among volume-matched conditions near Ulcerative Colitis (UC)

Ulcerative Colitis (UC) lists 10 open slots (56% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ulcerative Colitis (UC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ulcerative Colitis (UC) is recruiting above its size-band peers.

    10 of 18 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ulcerative Colitis (UC) research.

    AbbVie accounts for 5 of 18 trials (27.8%). 13 distinct sponsors appear on at least one study for this condition label.

  3. Typical Ulcerative Colitis (UC) enrolment sits around 152 participants.

    Median target enrolment is 152 among the 18 trials that report a genuine target (sentinel values excluded). 6 of those (33.3%) plan for fewer than 100 participants.

  4. Ulcerative Colitis (UC) research is mostly interventional.

    13 interventional and 5 observational studies make up this index (72.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 33

Open and recent trials

18 total, page 1 of 1

RECRUITING Phase 1 270 participants

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Xencor

NCT06619990

RECRUITING 200 participants

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

University of North Carolina, Chapel Hill

NCT07237516

RECRUITING NA 200 participants

STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission

University of Chicago

NCT06693310

RECRUITING Phase 2 180 participants

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

Northwestern University

NCT07427017

RECRUITING NA 152 participants

Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)

Yale University

NCT05377840

RECRUITING Phase 2 140 participants

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Mirador Therapeutics

NCT07113522

RECRUITING 120 participants

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

Connecticut Children's Medical Center

NCT07224113

RECRUITING NA 70 participants

Evaluation of the SMART IBD App in Pediatric IBD

Children's Hospital Medical Center, Cincinnati

NCT07195123

RECRUITING 50 participants

Family Members At INcreased-risk for Developing Inflammatory Bowel Disease

Massachusetts General Hospital

NCT06655415

RECRUITING Phase 1 24 participants

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

AltruBio

NCT07350577

ACTIVE NOT RECRUITING 8,250 participants

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

AbbVie

NCT01848561

ACTIVE NOT RECRUITING Phase 3 1,242 participants

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

AbbVie

NCT03398135

ACTIVE NOT RECRUITING Phase 3 950 participants

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

AbbVie

NCT03006068

ACTIVE NOT RECRUITING 120 participants

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

Vanderbilt University Medical Center

NCT07123350

COMPLETED Phase 3 952 participants

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

AbbVie

NCT02065622

COMPLETED Phase 2 42 participants

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

AbbVie

NCT03695185

COMPLETED NA 30 participants

Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D

University of California, San Francisco

NCT01877577

COMPLETED Phase 1 11 participants

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

University of California, San Francisco

NCT01971814

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 3

Named interventions

Most-linked intervention names on Ulcerative Colitis (UC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Placebo Other
2 trials
Ravagalimab 300 mg Drug
1 trials
Ravagalimab 600 mg Drug
1 trials
Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care Drug
1 trials
placebo for risankizumab Drug
1 trials
risankizumab Drug
1 trials
Upadacitinib (ABT-494) Drug
1 trials

US sites by state

Facility locations filed on Ulcerative Colitis (UC) trials. A trial with sites in several states counts in each.

California 7 trials
Illinois 5 trials
Florida 5 trials
Arizona 5 trials
Connecticut 4 trials
Alabama 4 trials
Colorado 3 trials
Texas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ulcerative Colitis (UC) page

18 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 10 Ulcerative Colitis (UC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AbbVie sponsors the most Ulcerative Colitis (UC) trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ulcerative Colitis (UC) condition card totals 18 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.